SUMMIT European Cannabis Insights Summit 2026 — Exclusive industry intelligence Register Now
EVENT Cannabis Europa London 2026 — Europe's cannabis industry unites Get Tickets

Recent Searches

    Report Reveals 72% of Canadians Accept Cannabis Legalisation

    By

    This Nov 3rd, join us for the third edition of Business of Cannabis: New York at the New York Academy of Medicine. A day long leadership summit focused on retail, investment & policy across New York and North America. Tickets on-sale now – www.cannabisnewyork.live

    A new report from Pollara Strategic Insights – Legal cannabis in Canada: 5 years later – has revealed that most Canadians, 72%, accept Canada’s cannabis legalisation policy.

    The report tracks public and user perceptions, attitudes, and behaviours five years following cannabis legalisation in October 2018.

    Pollara Strategic Insights reports that around half of those accepting legalisation have approved of the policy since 2020, while only 23% currently disapprove of the policy, which is down from 34% in 2019.

    Regarding economic and tax revenue measures, the report reveals that Four-in-ten see positive impacts of legalization on both federal (39%) and provincial (40%) tax revenues.

    However, in regard to health impacts, responses revealed more negative perceptions than positive, with 32% to 38% perceiving a more pronounced effect on the health of youth and children. Despite this, amongst past 12-month cannabis users, four out of ten respondents said they perceived a positive impact on overall health, mental health and physical health of adults.

    Usage and purchase

    The report also reveals that those who had used cannabis before and after legalisation were 30% more likely to have reduced rather than increased their frequency of use.

    Demographic data showed that Gen Z, Millennials and Boomers are more likely to have reduced usage frequency since legalisation compared to before legalisation, whereas Gen Xers are likely to use cannabis more often now than before.

    Additionally, dry flower is the most purchased product in the last 12 months at 38%, followed by edibles at 26% and vapes ar 9%. The report states, however, that “when considering all formats used – regardless of frequency – edibles are now slightly ahead of dry bud.”

    A total of 82% of respondents also revealed that in the past 12 months, they bought legal cannabis, which amounts to a 7-point increase in legal buying since November 2022 and a 15-point increase since Mar 2021.

    However, 13% of respondents reported buying illegal cannabis.

    The report states: “Past 12-month users still tend to view legal prices as higher (36%) or the same (17%) as illegal prices, but perceptions of higher prices remain significantly lower than 2019 – 2021 and four-in-ten are currently unsure.”

    To read the full report please visit: https://www.pollara.com/wp-content/uploads/2023/10/Pollara-LegalCannabis5YrsLater-RptF1-1.pdf

    Stephanie Price

    Stephanie is a journalist for Business of Cannabis, writing about science, research, policy and industry developments in cannabis, CBD and psychedelics. In 2013 Stephanie gained her BA in English and Media, focusing on journalism and propaganda, where her magazine ‘Game Theory’ focused on developments and disruptors over the coming decade including cannabis, psychedelics, blockchain/crypto and free speech. In 2015 Stephanie received her National Council for the Training of Journalists (NCTJ) diploma whilst working as a reporter in North Wales. Stephanie has a specialism in Medical Cannabis: The Health Effects of THC and CBD through the University of Colorado, and a certificate from the Medical Cannabis Clinicians Society on “Medical Cannabis Explained”.

    The Briefing / Newsletter

    Insights
    you don't want
    to miss.

    A comprehensive, thoughtfully curated overview of the stories defining today's cannabis sector — breaking news, investigative features, expert commentary, and context-rich analysis to help you navigate events with clarity and confidence.

    • Policy & regulation
    • Markets & deals
    • Clinical & science
    Subscribe free